文献速递临床试验与 GCP基础与转化研究

重组人促红细胞生成素对心境障碍缓解期患者及精神障碍患者一级亲属认知与神经活动的影响:随机对照试验研究方案

Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-11-06

该随机对照试验包含两个平行子研究,分别纳入52名精神障碍患者一级亲属和52名部分或完全缓解的双相或单相心境障碍患者,均存在客观认知功能障碍。受试者随机接受每周高剂量重组人促红细胞生成素(EPO)或安慰剂输注12周,主要结局为注意力、言语记忆和执行功能复合评分变化,并在基线和治疗2周时进行功能磁共振成像。

要点

  • EPO每周高剂量输注12周,评估对认知复合评分的影响。
  • 两个子研究分别针对一级亲属和心境障碍缓解期患者。
  • 功能磁共振成像探索早期神经活动变化预测认知改善。

核心结论

  • 若试验证实EPO的促认知效应,可能影响心境障碍未来治疗及高危人群预防策略。

研究设计与样本

  • 随机、对照、双盲、平行组设计,包含两个平行子研究;子研究1纳入一级亲属52人,子研究2纳入部分或完全缓解的双相或单相心境障碍患者52人,均经客观验证存在认知功能障碍。

主要发现

  • 原文未报告试验结果,仅描述研究方案。

关键数值与推荐

  • 干预为每周高剂量EPO(40,000 IU/mL)或安慰剂(生理盐水)输注,持续12周。
  • 主要结局为注意力、言语记忆和执行功能认知复合评分的变化。
  • 评估时间点为基线、治疗2周后、治疗完成时及6个月随访。
  • 功能磁共振成像在基线和治疗2周后进行。
  • 纳入52名一级亲属和52名患者分别达到≥80%统计效能检测临床相关组间差异。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bipolar disorder (BD) and unipolar disorder (UD) are associated with cognitive deficits and abnormal neural activity in a "cognitive control network." There is an increased prevalence of cognitive dysfunction in psychiatric patients' first-degree relatives, which constitutes a risk factor for psychiatric illness onset. However, there is no treatment with enduring pro-cognitive efficacy. We found preliminary evidence for beneficial effects of eight weekly doses of recombinant human erythropoietin (EPO) on cognition in BD in a recent randomized controlled trial (RCT). The present RCT consists of two sub-studies that extend our previous work by investigating important novel aspects: (1) the effects of 12 weekly doses of EPO on cognition in first-degree relatives of patients with BD, UD, or schizophrenia; and (2) the effects of extending the treatment schedule from 8 to 12 weeks in remitted patients with BD or UD; and (3) assessment of early treatment-associated neural activity changes that may predict cognitive improvement. METHODS: The trial comprises two parallel sub-studies with randomized, controlled, double-blinded, parallel group designs. First-degree relatives (sub-study 1; n = 52) and partially or fully remitted patients with BD or UD (sub-study 2; n = 52) with objectively verified cognitive dysfunction are randomized to receive weekly high-dose EPO (40,000 IU/mL) or placebo (saline) infusions for 12 weeks. Assessments of cognition and mood are conducted at baseline, after two weeks of treatment, after treatment completion, and at six-month follow-up. Functional magnetic resonance imaging (fMRI) is conducted at baseline and after two weeks of treatment. Psychosocial function is assessed at baseline, after treatment completion and six-month follow-up. The primary outcome is change in a cognitive composite score of attention, verbal memory, and executive functions. Statistical power of ≥ 80% is reached to detect a clinically relevant between-group difference by including 52 first-degree relatives and 52 patients with BD or UD, respectively. Behavioral data are analyzed with an intention-to-treat approach using mixed models. fMRI data are analyzed with the FMRIB Software Library. DISCUSSION: If this trial reveals pro-cognitive effects of EPO, this may influence future treatment of mood disorders and/or preventive strategies in at-risk populations. The fMRI analyses may unravel key neurobiological targets for pro-cognitive treatment. TRIAL REGISTRATION: ClinicalTrials.gov , NCT03315897. Registered on 20 October 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Petersen JZ, Schmidt LS, Vinberg M, et al. Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. Trials. 2018. PMID: 30400939. doi:10.1186/s13063-018-2995-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。